TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML,...

Full description

Bibliographic Details
Main Authors: Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso
Format: Article
Language:English
Published: PAGEPress Publications 2017-07-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
acute myeloid leukemia
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/2996

Internet

http://www.mjhid.org/index.php/mjhid/article/view/2996

Similar Items